Synaffix Out-Licenses ADC Technology Platform to Emergence for Cancer
Shots:
- Synaffix will be eligible to receive ~$360M up front and milestones along with royalties on commercial sales. Additionally, Emergence gets the rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline
- The agreement enables Emergence & provides access to the use of Synaffix's ADC technologies comprising GlycoConnect, HydraSpace, and SYNtecan E linker-payload. Additionally, the companies advance the programs for cancer treatment
- Emergence will be responsible for the research, development, manufacturing, and commercialization of the ADCs while Synaffix will lead the manufacturing of components related to its technologies
Ref: PRNewswire | Image: Synaffix
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
